Human Intervention Studies Unit, Ulster University
Coleraine, Co.Londonderry, BT52 1SA, United Kingdom
NCT Number: NCT04948086
Approximately 12% of the world's population have a have a common C677T polymorphism in the gene encoding the folate metabolising enzyme, methylenetetrahydrofolate reductase (MTHFR). Homozygosity for the polymorphism (TT genotype) appears to result in an increased requirement for the B-vitamins folic acid and riboflavin and more importantly results in an increased risk of developing high blood pressure (BP). Previous work from our Centre has demonstrated significantly higher BP in those with the TT genotype. This work has been conducted in cohorts with premature cardiovascular disease (CVD) and hypertension without overt CVD, but the effect in younger, healthier individuals is unexplored. To date our studies have also focused on BP as the primary outcome, but newer markers of vascular health including central pressure and hemodynamics have emerged as superior prognostic indicators of CVD. The effect of the TT genotype on these measures is thus an important area for investigation and may help us understand the mechanism linking the genotype with BP, which is currently unknown. As adults with the TT genotype appear to have increased requirements for riboflavin and folic acid, and BP in TT adults appears to be riboflavin dependent, the influence of these vitamins on central measures is an area for consideration. Study Design This is an observational study investigating the blood pressure profiles of healthy adults aged 18-65 years, stratified by MTHFR genotype. Apparently healthy adults will be recruited from workplaces and the general community across Northern Ireland and screened for the polymorphism via buccal swab. Those with the TT genotype and a similar number of non-TT (i.e. CC/CT) genotype individuals will be contacted and asked to come to attend a one-off appointment. Brachial BP will be assessed by an electronic BP monitor, central BP and central haemodynamics (augmentation index, augmentation pressure and pulse wave velocity) will be assessed by SphygmoCor XCEL. In addition, anthropometric measurements, health and lifestyle information and a blood sample will be obtained. Data will be statistically analysed using SPSS software to if determine differences between gentoype groups exist.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Coleraine, Co.Londonderry, BT52 1SA, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: One day, one measurement
Office blood pressure
Time frame: One day, one measurement
Measured using SphygmoCor device
Time frame: One day, one measurement
Measured using SphygmoCor device
Time frame: One day, one measurement
Measured using SphygmoCor device
Time frame: One day, one measurement
Measured using SphygmoCor device
Time frame: One day, one measurement
Measured by by EGRac
Time frame: One day, one measurement
Measured by microbiological assay
Time frame: One day, one measurement
Measured by HPLC
Time frame: One day, one measurement
Measured by GCMS
Time frame: One day, one measurement
Measured by GCMS-MS
University of Ulster
Other
Blood Pressure Lowering Effect of B-vitamins in Adults With a Genetic Pre-disposition to Elevated Blood Pressure.
Acronym: RAFA Obs
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04817137
Blood Pressure
Boston, Massachusetts, United States
View Trial DetailsNCT07713576
Blood Pressure
Chenzhou, Hunan, China
View Trial DetailsNCT06550297
Blood Pressure, Cardiovascular Diseases
New York, United States
View Trial DetailsNCT07317648
Blood Pressure
York, England, United Kingdom
View Trial Details